Epistem is a biotechnology company with a specialist understanding of epithelial tissue and adult stem cell analyses, operating three distinct business divisions.
The Contract Research Division delivers innovative preclinical research services in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare. Working with over 150 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology.
The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP accredited quality standards and has recently launched this technology in kit form as RNA-Amp®. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.
The Company has pioneered a technique using single plucked scalp hair, as a surrogate biomarker tissue, to monitor responses to drug treatment. Information using hair can be obtained either from preclinical models, human scalp hair treated ex vivo or from clinical trial samples.
Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.
Specialties
GCLP, drug development, therapeutics, oncology, contract research, gene expression, biomarkers, dermatology, mucositis, preclinical, inflammatory bowel disease, IBD, angiogenesis, histology, wound healing, radiation, molecular diagnostics, hair research/growth
